Methotrexate with citrovorum factor rescue in gestational trophoblastic disease

Wong, L.C.; Choo, Yew Cheong; Ma, H.K.

doi:10.1016/s0002-9378(85)80178-2

Cited by 61 publications

(24 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Generally, both conventional MTX and MTX-CF regimens are considered to be the first choice for patients with low-risk GTD [2][3][4]. However, the incidence of drug change because of the development of drug resistance and/or intolerable side effects was reported to be 12.4-26.4% [1][2][3][4]8].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of Chemotherapies with Methotrexate, VP-16 and Actinomycin-D in Low-Risk Gestational Trophoblastic Disease

Matsui

Iitsuka

Seki

et al. 1998

Gynecol Obstet Invest

View full text Add to dashboard Cite

Objective: To compare the efficiency and toxicity of four chemotherapeutic regimens in low-risk gestational trophoblastic disease. Methods: Since 1974, 247 patients with low-risk gestational trophoblastic disease have been treated with 5-day intramuscular methotrexate (MTX) (conventional MTX), 5-day intravenous drip infusion of VP-16, 5-day intravenous actinomycin-D (Act-D) or 8-day alternating intramuscular MTX-folic acid (MTX-CF) at Chiba University School of Medicine. We compared the primary remission rate, the response of human chorionic gonadotropin and the prevalence of drug toxicities in these 4 regimens. Results: The primary remission rate was 73.6% in the conventional MTX regimen, 90.1% in VP-16, 84.0% in Act-D, and 60.0% in MTX-CF. The primary remission rate was significantly higher in the VP-16 and Act-D regimens than in the conventional MTX and MTX-CF regimens. The response rate was significantly higher in the VP-16 regimen than in the other 3 regimens. The drug toxicity with VP-16 and Act-D was less than that with conventional MTX and MTX-CF regimens. Conclusions: The VP-16 regimen was highly effective and less toxic for gestational trophoblastic disease compared with other chemotherapeutic regimens.

show abstract

Section: Discussionmentioning

confidence: 99%

“…However, there are few reported studies which compare the efficacy Conventional MTX 6 Gynecol Obstet Invest 1998;46: [5][6][7][8] Matsui/Iitsuka/Seki/Sekiya …”

Section: Introductionmentioning

confidence: 99%

Comparison of Chemotherapies with Methotrexate, VP-16 and Actinomycin-D in Low-Risk Gestational Trophoblastic Disease

Matsui

Iitsuka

Seki

et al. 1998

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…An alternative regimen consists of slightly higher doses of methotrexate (1.0-1.5 mg/kg IM) every other day alternating with folinic acid (0.1-0.15 mg/kg IM) over 8 days with at least a 1-week interval between courses [8][9][10]. This protocol is reported to have decreased toxicity (especially stomatitis) but is more expensive and inconvenient, and is associated with a more frequent need for a change in chemotherapy to achieve remission.…”

Section: Low-risk Diseasementioning

confidence: 99%

Gestational trophoblastic neoplasia: an update

Morgan

Lurain²

2008

Curr Oncol Rep

View full text Add to dashboard Cite

Gestational trophoblastic neoplasia (GTN) includes invasive mole, choriocarcinoma, and placental site trophoblastic tumors. The overall cure rate in treating these tumors currently exceeds 90%. Thorough evaluation and staging allow selection of appropriate therapy that maximizes chances for cure while minimizing toxicity. Nonmetastatic (stage I) and low-risk metastatic (stages II and III, World Health Organization score < 7) GTN can be treated with single-agent chemotherapy, resulting in a survival rate approaching 100%. High-risk metastatic GTN (stage IV, WHO score > or = 7) requires initial multiagent chemotherapy with or without adjuvant radiation and surgery to achieve a survival rate of 80% to 90%.

show abstract

“…They noted that 26% of patients had to switch treatment because of drug resistance (20%) or drug-induced toxicity (6%). Similarly, Wong et al 33 from Hong Kong treated 68 low-risk patients with MTX-FA. Sustained remission was achieved in 76% with MTX-FA alone; 11.8% developed drug resistance requiring multiagent chemotherapy to achieve cure, and 8.8% had a treatment change because of MTX toxicity.…”

Section: Nonmetastatic Diseasementioning

confidence: 99%

Gestational Trophoblastic Neoplasia

Lurain¹

2006

Oncology

View full text Add to dashboard Cite

Methotrexate with citrovorum factor rescue in gestational trophoblastic disease

Cited by 61 publications

References 4 publications

Comparison of Chemotherapies with Methotrexate, VP-16 and Actinomycin-D in Low-Risk Gestational Trophoblastic Disease

Comparison of Chemotherapies with Methotrexate, VP-16 and Actinomycin-D in Low-Risk Gestational Trophoblastic Disease

Gestational trophoblastic neoplasia: an update

Gestational Trophoblastic Neoplasia

Contact Info

Product

Resources

About